DUBLIN--(BUSINESS WIRE)--The "Female Sexual Dysfunction - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Female Sexual Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 5, 2 and 1 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Female Sexual Dysfunction - Overview
- Female Sexual Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Sexual Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Sexual Dysfunction - Companies Involved in Therapeutics Development
- Callitas Therapeutics Inc
- Dare Bioscience Inc
- Emotional Brain BV
- EndoCeutics Inc
- Fabre-Kramer Pharmaceuticals Inc
- GlaxoSmithKline Plc
- Kuhnil Pharmaceutical Co Ltd
- M et P Pharma AG
- Palatin Technologies Inc
- Pivot Pharmaceuticals Inc
- Re-Pharm Ltd
- S1 Biopharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/q8wm98/female_sexual?w=4
